AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.
Lantern Pharma, a pharma company which uses artificial intelligence to develop shelved oncology drugs has joined Genomics England’s groundbreaking industry partnership.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
